Harvard Bioscience, Inc. — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The company develops, manufactures and sells life-science research instruments, systems and laboratory consumables worldwide. The 2013 comparative results reflect HART as discontinued operations following its 2013 spin-off.
Financial performance and position
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $108.7 million | $105.2 million |
| Gross profit / margin | $49.3 million / 45.4% | $47.7 million / 45.4% |
| Operating income | $6.6 million | $1.5 million |
| Continuing-operations income | $2.4 million | $0.7 million |
| Net income (loss) | $2.4 million | $(1.8) million |
| Operating cash flow | $4.4 million | $4.1 million |
- Revenue rose 3.3% as reported and 2.4% excluding currency effects, reflecting acquisitions and organic growth. Bookings increased 3.1% excluding currency effects to $109.9 million; year-end backlog rose to $7.2 million from $5.1 million, partly due to acquisitions and order timing.
- Operating income improved despite higher sales and R&D costs, with lower G&A, reduced restructuring and HART separation costs, and a $0.8 million gain on sale of a UK facility contributing. Acquisition-related costs of $1.1 million were included in other expense.
- Cash from operations was $4.4 million; investing activities used $13.5 million, including $12.7 million for acquisitions. Cash declined to $14.1 million from $25.8 million. Inventory increased $4.8 million to $20.5 million.
- Working capital was $39.0 million, versus $44.7 million. Total debt was $21.5 million, down from $24.8 million; cash less debt was a net debt position of $7.4 million. The company reported $11.8 million of available borrowing capacity and compliance with credit-facility covenants at year-end.
- Current and long-term debt maturities total $21.5 million; $5.0 million is scheduled for 2015 and $9.2 million for 2016. The credit facility is secured by substantially all company and guarantor assets. Approximately $12.7 million of year-end cash was held by foreign subsidiaries and was not available for U.S. operations without repatriation and potential tax.
- Gross margin was unchanged year over year. The effective tax rate was 46.7% in 2014; the company cited a higher valuation allowance on foreign tax credits as a primary factor. Foreign-currency translation reduced comprehensive income by $5.9 million.
Fourth-quarter information
Unaudited fourth-quarter revenue was $30.4 million, compared with $27.9 million in 2013. Operating income was $2.1 million, versus an operating loss of $0.9 million. The company reported a $19,000 net loss for the quarter, primarily reflecting $1.2 million of income tax expense against $1.2 million of pretax continuing-operations income.
Material changes, outlook and risks
- In October 2014, the company acquired MCS and TBSI for a combined approximately $12.7 million, net of cash acquired, expanding its electrophysiology products. In January 2015, it acquired HEKA for approximately $6.0 million. Management expected the three acquisitions together to add approximately $12 million in annual revenue and be accretive to EPS; these are expectations, not reported outcomes.
- The multi-year restructuring program includes relocating Denville distribution operations to North Carolina and consolidating Biochrom manufacturing in Holliston. Management expected $0.8–$1.0 million of costs in 2015 and annual savings of $0.8–$1.0 million beginning in 2016. Capital spending was expected to increase with ERP implementation and facility moves.
- Management stated that available cash, operating cash generation and debt capacity were expected to support current operations, potential acquisitions and capital expenditures for at least the next 12 months and beyond, subject to operating-plan changes and other uncertainties. The filing provides no specific 2015 revenue or earnings guidance.
- Key risks include dependence on research funding and customer budgets; international and foreign-exchange exposure; acquisition integration and execution of restructuring and ERP implementation; substantial secured debt, covenants and near-term maturities; and competition, technological change and intellectual-property risks. The company reported no material legal proceedings. It also disclosed potential tax consequences if the HART spin-off fails to retain tax-free treatment.
- Management and the auditor concluded that internal control over financial reporting was effective at year-end; the assessment excluded MCS and TBSI. The financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Whether organic growth and bookings convert into sustained revenue growth, particularly as acquisition contributions are incorporated.
- Whether MCS, TBSI and HEKA achieve the stated revenue and EPS expectations, and how acquisition funding affects debt and cash.
- Progress, total costs and realized savings from restructuring, facility consolidation and ERP implementation.
- Liquidity and covenant headroom, including the 2015–2016 debt maturities and the location and accessibility of foreign cash.
- Effects of currency movements, tax-asset valuation allowances and any developments that could affect the HART spin-off’s tax treatment.